Scarica l'app Stockscreener
66.37
1.03%
-0.69
Dopo l'orario di chiusura:
66.38
0.010
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$67.06
Aprire:
$67.1
Volume 24 ore:
2.06M
Relative Volume:
0.36
Capitalizzazione di mercato:
$25.89B
Reddito:
$4.30B
Utile/perdita netta:
$571.50M
Rapporto P/E:
46.46
EPS:
1.4285
Flusso di cassa netto:
$570.80M
1 W Prestazione:
-1.56%
1M Prestazione:
+4.57%
6M Prestazione:
-23.97%
1 anno Prestazione:
-14.66%
Intervallo 1D:
$66.00
$67.15
Intervallo di 1 settimana:
$66.00
$68.18
Portata 52W:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
66.37 | 26.15B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.29 | 218.72B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.35 | 142.33B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.47 | 135.42B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.06 | 123.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.25 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
The Truth About DexCom Inc: Why Everyone Is Suddenly Watching DXCM - AD HOC NEWS
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
DexCom (NASDAQ:DXCM) & Avanos Medical (NYSE:AVNS) Head-To-Head Contrast - Defense World
Dexcom Stock Finds Its Range: What The Latest Drift, Data, And Deals Signal For 2026 - AD HOC NEWS
FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software - marketscreener.com
E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM - MarketBeat
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM - MarketBeat
Beacon Investment Advisory Services Inc. Trims Stock Position in DexCom, Inc. $DXCM - Defense World
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Finviz
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm - GlobeNewswire Inc.
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
December 26, 2025 Deadline: Join Class Action Lawsuit Against DexCom, Inc. (DXCM)Contact Levi & Korsinsky - ACCESS Newswire
Securities Lawsuit Alert: DexCom, Inc. (DXCM) InvestorsContact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DAVENPORT & Co LLC Increases Position in DexCom, Inc. $DXCM - MarketBeat
Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - ACCESS Newswire
Investor Alert: Deadline Approaching to Join DexCom, Inc. (DXCM) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Class Action Lawsuit Filed: DexCom, Inc. (DXCM)Join by December 26, 2025Contact Levi & Korsinsky - ACCESS Newswire
Voya Investment Management LLC Sells 186,132,582 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM): Reassessing Valuation After Class Action Lawsuits and New FDA Clearance for Smart Basal - Sahm
DXCM Investors Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 47% Undervalued - 富途牛牛
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT - GuruFocus
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
DexCom, Inc. (DXCM) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 26, 2025 Deadline - Stockhouse
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc.(DXCM) Shareholders - The Malaysian Reserve
Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained - ACCESS Newswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DexCom, Inc. $DXCM Shares Sold by Congress Asset Management Co. - MarketBeat
Dexcom G6 Glucose Monitors Lawsuit - Drugwatch.com
Class Action Filed Against DexCom, Inc. (DXCM) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Leadership Transition with New CEO Appointment - GuruFocus
Shareholders SueWallSt in New Class Action Against DexCom, Inc.Act Now - ACCESS Newswire
Dexcom Names Jacob Leach as Incoming Chief Executive - TipRanks
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Inc Announces CEO Appointment - TradingView — Track All Markets
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
2025-12-22 | Lost Money on DexCom, Inc. (DXCM)? Urged to Join Class Action Before December 26, 2025Contact Levi & Korsinsky | NDAQ:DXCM | Press Release - Stockhouse
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM) - GlobeNewswire
Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential - Insider Monkey
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
10 Best Growth Stocks to Buy in 2026 - Insider Monkey
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):